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Background: A systematic review and network meta-analysis (NMA) were conducted to compare oral anticoagulants and aspirin for the 
secondary prevention of venous thromboembolism (VTE).
methods: Databases were searched (July 2014) to identify phase III randomized controlled trials (RCTs) evaluating the novel oral anti-
coagulants (NOACs), warfarin and aspirin. A fixed-effect Bayesian NMA was conducted for relevant outcomes.
results: Eleven eligible RCTs reported the following treatments: apixaban 2.5 mg twice daily (BD); apixaban 5 mg BD; rivaroxaban 20 mg 
once daily (OD); dabigatran 150 mg BD; aspirin 100 mg OD; warfarin standard/low dose. The relative risk of ‘VTE and VTE-related death’ 
was significantly lower for apixaban 2.5 mg BD compared with aspirin 100 mg. The risk of ‘major or clinically relevant non-major (CRNM) 
bleed’ was significantly lower for apixaban compared with the other NOACs [rivaroxaban (↓77%), dabigatran (↓58%)] and standard dose 
warfarin (↓77%). A lower risk of treatment discontinuation was observed for apixaban compared with all treatments.
conclusion: These findings may help redefine clinical equipoise and alter the guidelines for secondary prevention, as apixaban provides 
improved efficacy in terms of reduction in ‘VTE or VTE-related death’ and similar risk of major bleeding compared with aspirin. Apixaban 
reports a significantly better safety profile compared with other NOACs including VKA, dabigatran or rivaroxaban.
Table: NMA results. *statistically significant
Outcome
Relative Risk (95% CrI): apixaban 2.5 mg BD vs comparator
Dabigatran
150 mg BD
Rivaroxaban
20 mg OD Aspirin 100 mg OD
Warfarin
INR 2.0-3.0
VTE and VTE-related death 1.77 (0.70, 4.68) 1.01 (0.40, 2.71) 0.28 (0.14, 0.51)* 2.37 (0.94, 6.13)
Major or CRNM bleed 0.42 (0.18, 0.97)* 0.23 (0.09, 0.59)* 0.82 (0.33, 2.04) 0.23 (0.10, 0.55)*
Major bleed 0.24 (0.02, 1.82) 0.03 (0.00, 0.65)* 0.34 (0.03, 2.51) 0.13 (0.01, 0.92)*
CRNM bleed 0.47 (0.19, 1.12) 0.28 (0.10, 0.73)* 0.71 (0.20, 2.43) 0.26 (0.11, 0.64)*
Discontinuation 0.78 (0.57, 1.09) 0.72 (0.51, 1.04) 0.66 (0.48, 0.91)* 0.75 (0.54, 1.05)
